Leukemia cutis is the infiltration of the skin by malignant hematopoietic cells. Any type of leukemia can disseminate to the skin, but this occurs most frequently in myeloid leukemias with monocytic differentiation, which presents with specific cutaneous involvement in B25-31% of cases, and less frequently in AML, in 10% of cases. [1] [2] [3] It is widely recognized that the onset of cutaneous involvement in leukemia as a specific skin infiltration carries a poor prognosis. 4 We report the case of a woman diagnosed with AML who underwent allogeneic BMT and who presented with six consecutive cutaneous relapses, always confined to the same area and in the absence of peripheral blood or BM involvement.
A 37-year-old woman diagnosed with AML type M2, showing the chromosomal translocation t (10;11)(q22;q23) and mixed lineage leukemia gene rearrangement by FISH analysis, received an allogeneic BMT from a HLA-identical female sibling in December 2000, after an ablative conditioning regimen, achieving CR and full donor chimerism. The patient developed chronic pulmonary GVHD since 2001. She remained in hematological CR and full donor chimerism for 3 years. From 2003 to June 2008, she suffered six consecutive localized cutaneous relapses confined to the skin of her left leg without any evidence of peripheral blood or BM involvement. All the relapses have been confirmed by skin biopsy and treated with local radiotherapy, resulting in complete resolution. Nonetheless, subsequent relapses appeared after an interval of B6 months. The patient never received systemic chemotherapy or donor lymphocyte infusion as treatment.
In the last relapse, in August 2007, a well-demarcated linear erythematous plaque appeared on the skin of her left leg (15 Â 1, 5 cm), with some indurated areas (Figure 1 ). There was no lymph node enlargement, hepatosplenomegaly or gingival hypertrophy. The skin biopsy showed a dense nodular infiltrate in the dermis with extension to the subcutis, and sparing of the upper papillary dermis (Grenz zone) composed predominantly of medium blast-like cells, with a perivascular and periadnexal accentuation (Figure 2) , and some cells distributed between collagen bundles. The immunohistochemical analysis of paraffin sections showed positive staining with myeloperoxidase, CD34 and muramidase, but negative staining for CD68, CD61, terminal deoxynucleotidyl transferase, glycophorin A, CD3, CD56 and CD20. MIB1 (Ki67) stained 30% of neoplastic cells. We reviewed the earlier skin biopsies and these were similar to the last one. The FISH analysis identified a mixed lineage leukemia-gene rearrangement in the skin, the same cytogenetic abnormality that was present in the earlier leukemic clone. PCR analysis of the skin confirmed a mixed chimerism with 60% of donor DNA. The patient remained in hematological CR with full donor chimerism in both marrow and peripheral blood. The relapses were always limited to the skin.
The appearance of specific skin infiltrations in leukemia is generally considered a poor prognostic sign and correlates with rapid leukemia progression and shorter survival. Most of the patients with leukemia cutis develop systemic involvement and die within a few months. 4 Our patient had an unexpectedly good disease evolution. Currently, long after the first cutaneous relapse 5 years ago, she is still alive and remains in hematological CR.
We can only speculate about the pathogenic mechanism by which specific skin infiltrates were always confined to the same location in our patient. One possible explanation would be a phenomenon of oncotaxis: leukemic cells are attracted to the area of an earlier radiotherapy mediated by specific local chemotactic factors. In some exceptional cases, specific infiltrates can be found accompanying inflammatory cutaneous diseases, traumas or scars, without the classic poor behavior. 4, 5 Another hypothesis is that systemic chemotherapy induces and maintains BM remission but fails to control cutaneous leukemic infiltrates, allowing some neoplastic clones of cells to survive in the skin and subsequently causing relapses. [6] [7] [8] The presence of a full chimerism status may not assure the absence of minimal residual disease and might not protect from www.nature.com/bmt extramedullary relapses as has been reported earlier. 9 Therefore, our case might be explained by the presence of minimal residual disease that we were not able to detect.
In summary, we report an exceptional case of a 37-yearold woman with the an earlier diagnosis of AML-M2 and allogeneic BMT who presented six consecutive cutaneous relapses during a 4-year period, always confined to the same area in the absence of peripheral blood or BM involvement. Remarkably, our patient had a good evolution of her disease remaining in continuous CR and alive 5 years after the first relapse. To the best of our knowledge, this benign clinical presentation of cutaneous relapses of AML has never been reported earlier. 
